http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
BeiGene Reports Second Quarter 2020 Financial Results
-
Edison Issues ADR Outlook on Hutchison China MediTech (HCM)
-
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab
-
Edison Issues ADR Update on Hutchison China MediTech (HCM)
-
Hutchison China MediTech (HCM) announces Elunate have been included in China's National Reimbursement Drug List by NHSA
-
Edison issues ADR update on Hutchison China MediTech (HCM)
-
Edison issues ADR update on Hutchison China MediTech (HCM)
-
Chi-Med (HCM) and AstraZeneca's (AZN) Savolitinib Shows Encouraging Activity in EGFR Mutation-Positive Lung Cancer with MET-Amplification
-
Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
-
Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma
-
Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium
-
Hutchison China Meditech Limited: Savolitinib PRCC Results Presentation at ASCO GU
-
Hutchison China MediTech Limited (Nasdaq: HCM) to Ring The Nasdaq Stock Market Closing Bell in Celebration of IPO